Johnson & Johnson's shares increased 3% on Wednesday after the company received the support of around 60,000 people for its $8.9 billion settlement to resolve talc-related lawsuits, which could bring an end to the case. Analysts were positive about the settlement that is significantly larger than the original offer of $2 billion. J&J said the settlement would enable it to proceed with its plans to list its consumer health unit Kenvue. The company also condemned the actions of plaintiffs' lawyers, saying that the talc claims lacked scientific merit.